evipedia.ai
← Back

GHRP-2 for Health & Longevity

Evidence Review created on 10/28/2026 using AI4L / Opus 5.5

Also known as: Pralmorelin, Pralmorelin Hydrochloride, Pralmorelin Dihydrochloride, Growth Hormone-Releasing Peptide-2, GHRP 2, KP-102, GPA-748, WAY-GPA-748, GHRP KAKEN 100

Motivation

GHRP-2 (pralmorelin) is a small, laboratory-made peptide that mimics ghrelin, the body’s “hunger hormone,” and prompts the pituitary gland to release bursts of the body’s own growth hormone. Because growth hormone output falls steadily with age, a way to raise it without injecting the hormone itself has drawn interest from people focused on muscle, body composition and healthy aging.

The compound emerged from decades of academic research into how growth hormone release is controlled. Today it is approved in only one country, Japan, and only as a one-time diagnostic test. Elsewhere it circulates as an unapproved “research peptide,” sold online and offered by some clinics, and it is banned in competitive sport. Much of the interest traces back to short studies of its effects on hormone levels.

This review examines what human, animal and regulatory evidence shows about the potential benefits of GHRP-2, its risks and side effects, the doses that have been studied and used, and how its use can be monitored, for adults considering it as part of a health and longevity strategy.

Benefits - Risks - Protocol - Conclusion

Expert commentary and reviews that discuss GHRP-2 or the growth hormone and ghrelin-receptor pathway it acts on.

No directly relevant content was found from Chris Kresser or Life Extension Magazine. Rhonda Patrick’s only discussion of GH-releasing drugs (a Q&A on ibutamoren and sermorelin) is members-only, so a freely available FoundMyFitness clip on the same pathway is listed instead.

Grokipedia

Pralmorelin

An AI-generated encyclopedia entry summarizing GHRP-2’s chemistry, pharmacology, Japanese diagnostic approval, adverse effects and regulatory status; useful for orientation, but not a primary source.

Examine

No Examine article on GHRP-2 exists. Examine.com does not typically cover prescription medications or unapproved research peptides; GHRP-2 is approved only in Japan, as a prescription diagnostic agent, according to its label on the site of Japan’s drug regulator, the Pharmaceuticals and Medical Devices Agency (PMDA label); the label data derive from studies by the manufacturer, Kaken Pharmaceutical.

ConsumerLab

No ConsumerLab article on GHRP-2 exists. ConsumerLab does not typically cover prescription medications or unapproved injectable research peptides, and GHRP-2 is not sold as a dietary supplement.

Systematic Reviews

No systematic reviews or meta-analyses for GHRP-2 were found on PubMed as of October 28, 2026.

Neither the claimed benefits of GHRP-2 nor its principal risks are represented by a systematic review or meta-analysis.

Mechanism of Action

GHRP-2 is a synthetic six-amino-acid peptide that activates GHSR-1a on the GH-producing cells of the pituitary and in the hypothalamus (the brain region that controls the pituitary). It amplifies the brain’s own GHRH signal and counters somatostatin (the hypothalamic hormone that brakes GH release), producing brief GH pulses that drive the liver to make IGF-1, per a narrative review (Ghigo 1997). GH output stays pulsatile even during a 30-day infusion (Bowers 2004). Much of the human GHRP-2 literature, including that study, is co-authored by Cyril Bowers, the peptide’s developer at Tulane University (Bowers 2012), and the label data come from its manufacturer, Kaken Pharmaceutical.

  • Selectivity: A dose also raises prolactin, ACTH (adrenocorticotropic hormone, the pituitary signal for cortisol) and cortisol (Arvat 1997); GHRP-2 also binds CD36, a scavenger receptor on vessel and immune cells (Titterington 2009).
  • Half-life: About 0.42–0.69 hours after intravenous injection in adults (PMDA label) and 0.55 hours in children (Pihoker 1998).
  • Distribution: 83–86% bound to plasma proteins (PMDA label); volume of distribution (the apparent space the drug spreads into) 0.32 L/kg (Pihoker 1998).
  • Metabolism: No plasma metabolites; about 2% is excreted unchanged in urine, the rest mainly via bile (PMDA label); no cytochrome P450 (CYP, the liver’s main drug-metabolizing enzymes) pathway has been described.

Two readings compete: raising GH counters its age-related decline (Bowers 2004), yet people with genetically low GH signaling have little cancer or diabetes (Guevara-Aguirre 2011), and blocking the ghrelin receptor improved muscle function in aged mice (Kerr 2026).

Historical Context & Evolution

GHRP-2 descends from work by Cyril Bowers, whose group discovered unnatural GH-releasing peptides in 1976 and showed that they act through a pathway distinct from GHRH (Bowers 2012). Their activity implied an unknown natural hormone; its receptor was identified in 1996, and the hormone, ghrelin, was isolated from the stomach in 1999 (Kojima 1999). GHRP-2 proved potent by intravenous, subcutaneous, intranasal and oral routes, per a review (Ghigo 1997).

Its original intended uses were diagnosing and treating GH deficiency. Japan approved it as a diagnostic agent, marketed since 2005 (PMDA label), but a placebo-controlled trial in GH-deficient children found no gain in growth (Tanaka 2014). Intensive-care researchers tested it to counter the muscle wasting of prolonged critical illness and found that it restored GH pulses and IGF-1 (Van den Berghe 1997).

Interest for health optimization arose because GH secretion falls with age and GHRP-2 raises GH while keeping natural pulses and feedback, which reviewers framed as potentially safer than injecting GH (Sigalos 2018). Opinion has since shifted on several fronts: trials of GH in GH-replete adults found gains in lean mass, largely fluid, without reliable gains in strength, as a narrative review summarizes (Dominikowski 2026); reduced GH signaling was linked to protection from cancer and diabetes (Guevara-Aguirre 2011); and the US Food and Drug Administration (FDA) flagged compounding safety concerns in 2023 (FDA bulk substances list). No long-term outcome trial has tested either the case for or against GHRP-2.

Expected Benefits

High 🟩 🟩 🟩

Diagnosis of Growth Hormone Deficiency ⭕️ Not Central to Health & Longevity

A single 100 µg intravenous dose separates adults with severe GH deficiency from healthy people, the use approved in Japan (PMDA label). In the KP-102 Study Group trial led by Chihara, which underlies the label, peak GH averaged 1.36 µg/L in 58 deficient patients versus 84.6 µg/L in 77 healthy subjects (Chihara 2007). An independent Hiroshima group led by Kinoshita confirmed agreement with the insulin tolerance test (the reference test that provokes low blood sugar) (Kinoshita 2013). This bears on diagnosing pituitary disease, not on longevity.

Magnitude: Against the insulin tolerance test in 71 patients with pituitary tumors, the GHRP-2 test showed 81.3% sensitivity (share of true deficiency detected) and 94.5% specificity (share of non-deficient people correctly cleared) (Kinoshita 2013).

Medium 🟩 🟩

Increased Appetite and Food Intake ⭕️ Not Central to Health & Longevity

In a saline-controlled crossover study (each man received both infusions), seven lean, healthy men given a 270-minute subcutaneous GHRP-2 infusion ate more at a buffet meal, mirroring ghrelin’s effect (Laferrère 2005). Uncontrolled reports describe appetite rising for months with oral dosing in GH-deficient children (Mericq 2003) and weight gain in one woman with anorexia nervosa (Haruta 2015). This bears on undernutrition and wasting rather than on health and longevity in well-nourished adults, for whom extra hunger is a drawback.

Magnitude: Energy intake 35.9% (±10.9%) higher than with saline: 136.0 versus 101.3 kJ/kg (32.5 versus 24.2 kcal/kg) (Laferrère 2005).

Low 🟩

Lean Mass Gain in Older Adults

No trial has measured the effect of GHRP-2 on body composition. The evidence is indirect, from a different compound: the oral ghrelin-receptor agonist ibutamoren (MK-677) raised fat-free mass over 12 months in healthy older adults without improving strength or function (Nass 2008, co-authored by its developer, Merck).

Magnitude: Fat-free mass +1.1 kg (95% CI, confidence interval, the range likely to contain the true value: 0.7 to 1.5) with ibutamoren versus −0.5 kg (−1.1 to 0.2) with placebo, reported as a significant difference without a difference estimate (Nass 2008).

Linear Growth in Short Children ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Uncontrolled intranasal treatment raised growth velocity in 15 short children (Pihoker 1997), but a 48-week placebo-controlled trial in 126 GH-deficient children found no growth benefit (Tanaka 2014). This bears on childhood growth, not adult longevity. The stronger, controlled evidence shows no effect.

Magnitude: Height standard-deviation score (height relative to age peers) changed +0.07 with placebo, +0.03 with low dose and +0.02 with high dose over 48 weeks, with no significant difference between groups (Tanaka 2014).

Speculative 🟨

A 30-day subcutaneous infusion kept GH and IGF-1 higher in 17 healthy older adults (Bowers 2004). These are hormone levels only; no study links GHRP-2-raised IGF-1 to health outcomes.

Cardioprotection

GHRP-2 improved heart function in hamsters with cardiomyopathy (heart-muscle disease) and rats with heart failure or ischemia (loss of blood flow) (Kato 2010, Xu 2005, Furuta 2006). Animal work only.

Protection Against Muscle Wasting ⚠️ Conflicted

GHRP-2 curbed muscle-breakdown signaling in rodents with arthritis or burn injury (Granado 2005, Sheriff 2009), yet blocking the ghrelin receptor improved aged mouse muscle (Kerr 2026). Net: animal data point both ways.

Anti-Inflammatory Tissue Protection

In rodents, GHRP-2 reduced lung and liver injury from endotoxin (a bacterial toxin) and improved rotator cuff tendon healing (Li 2010, Granado 2008, Li 2025). The basis is animal work only.

Anabolic Support in Prolonged Critical Illness ⭕️ Not Central to Health & Longevity

In critically ill adults, GHRP-2 normalized IGF-1 but lowered protein-breakdown markers only with thyrotropin-releasing hormone (TRH, the brain’s thyroid signal) added (Van den Berghe 2002). Only biomarkers were measured; this bears on intensive care.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been studied as a modifier of GHRP-2 response. People with growth hormone receptor defects (Laron syndrome) cannot convert GH into IGF-1 (Guevara-Aguirre 2011), so GHRP-2 would not raise their IGF-1.
  • Baseline biomarkers: Low IGF-1 from suppressed hypothalamic drive, as in prolonged critical illness, responds strongly (Van den Berghe 1997); higher body fat blunts GH responses (Chihara 2007, Norman 2014).
  • Sex differences: Peak GH after a standard dose does not differ by sex (Chihara 2007); estradiol therapy amplifies GHRP-2-driven GH secretion in postmenopausal women (Shah 2000), and GHRP-2/GHRH synergy is larger in older women than men (Bowers 2004).
  • Pre-existing conditions: GH responses are nearly absent with pituitary stalk disconnection (damaged link between hypothalamus and pituitary) or Cushing’s syndrome (cortisol excess) and reduced in hypothyroidism (underactive thyroid) and obesity, per a review (Ghigo 1997); appetite gains matter most in undernutrition or wasting.
  • Age: GH responses are somewhat lower after age 40 and after menopause (PMDA label) and, per a review, are reduced by the sixth decade, yet remain marked and larger than responses to GHRH (Ghigo 1997).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the human adverse-event data come from manufacturer-run diagnostic studies, single small trials and spontaneous reports, not from replicated controlled trials by independent groups.

Medium 🟥 🟥

Warmth, Sweating and Other Acute Reactions ⚠️ Conflicted

The Japanese prescribing information, drawn from the manufacturer’s studies of 100 µg intravenous doses, lists a feeling of warmth as most common, plus stomach rumbling, raised white blood cell count, nausea, drowsiness, sweating, hunger, low blood pressure, facial flushing and raised ALT (alanine aminotransferase, a liver enzyme) (PMDA label). Small uncontrolled studies reported no side effects with subcutaneous doses in children (Mericq 1998) or a low intravenous dose with GHRH (Mahajan 2000). Net: mild, transient reactions are common after a full intravenous dose and less evident at lower doses.

Magnitude: Feeling of warmth in 16.0% of recipients; stomach rumbling and raised white blood cell count each in at least 5%; other reactions in under 5% or at unknown frequency; no control group (PMDA label).

Low 🟥

Raised Blood Sugar and Reduced Insulin Sensitivity

GH opposes insulin action. FDA cites reports of increased insulin requirement after GHRP-2, causality not established (FDA bulk substances list). Controlled data are indirect, from a different compound: ibutamoren raised fasting glucose and lowered insulin sensitivity in older adults (Nass 2008).

Magnitude: Fasting glucose rose by an average of 0.3 mmol/L (5 mg/dL) within the ibutamoren group over 12 months; no placebo-group figure is reported, so the figure is not compared between groups (Nass 2008).

Death and Serious Complications in Critical Illness

FDA lists deaths of critically ill study subjects, infections and pancreatitis (pancreas inflammation) among reports after GHRP-2, causality not established (FDA bulk substances list). In the same setting, high-dose GH itself, a different compound, raised in-hospital mortality in two randomized trials (Takala 1999).

Magnitude: With GH, not GHRP-2: in-hospital mortality 39% versus 20% with placebo (RR, relative risk, the ratio of event rates: 1.9; 95% CI 1.3–2.9) and 44% versus 18% (RR 2.4; 95% CI 1.6–3.5) (Takala 1999).

Fluid Retention and Muscle or Joint Pain

GH excess causes swelling and musculoskeletal symptoms. No GHRP-2 study documents them; a 2026 narrative review found such reports only for tesamorelin (Dominikowski 2026). Indirect data, from ibutamoren, show numerically more edema (fluid swelling) and muscle pain than placebo, without statistical significance (Nass 2008).

Magnitude: With ibutamoren, mild transient edema in 44% versus 27% with placebo and muscle pain in 33% versus 9% with placebo, neither difference statistically significant (Nass 2008).

Cancer Risk from Sustained IGF-1 Elevation

IGF-1 promotes cell growth. A meta-analysis of case-control studies (comparing people with and without cancer) linked higher natural IGF-1 to prostate and premenopausal breast cancer (Renehan 2004), and people with genetic GH-receptor deficiency rarely develop cancer (Guevara-Aguirre 2011). Both concern the body’s own IGF-1; no GHRP-2 cancer data exist.

Magnitude: OR (odds ratio, the ratio of the odds of disease) 1.49 (95% CI 1.14–1.95) for prostate and 1.65 (95% CI 1.26–2.08) for premenopausal breast cancer, comparing the 75th with the 25th IGF-1 percentile (Renehan 2004).

Pituitary Apoplexy in People with Pituitary Tumors

A man with a pituitary adenoma (benign pituitary tumor) developed pituitary apoplexy (sudden tumor bleeding, with vision loss) minutes after a combined test of GHRP-2 and three other releasing hormones (Yamamoto 2012); the label warns of apoplexy with a similar agent (PMDA label). Case reports only.

Magnitude: Not quantified in available studies. Only case reports exist, mostly after combined tests with several hormones, so no rate can be derived.

Speculative 🟨

Cortisol and Prolactin Elevation

A dose acutely raises ACTH, cortisol and prolactin (Arvat 1997); a second group confirmed the cortisol rise (Iranmanesh 2010). These are hormone levels; clinical effects of repeated rises are unmeasured.

Immunogenicity and Contaminated Products

FDA warns of immunogenicity (immune reactions) from peptide aggregates and impurities (FDA bulk substances list); seized products contained GHRP-2 variants or undeclared GHRP-2 (Krug 2018, Thomas 2010). No human outcome data exist.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to alter GHRP-2 safety. An inherited cancer predisposition or strong family history may magnify concern about sustained IGF-1 elevation, an inference from mechanism drawn in a narrative review (Dominikowski 2026).
  • Baseline biomarkers: Prediabetic glucose, high baseline IGF-1 or high prolactin leave less margin for the glucose, IGF-1 and prolactin rises that ghrelin-receptor agonists produce (Nass 2008, Arvat 1997).
  • Sex differences: Pregnancy is a contraindication (PMDA label). Estradiol therapy amplifies GHRP-2-driven GH release in postmenopausal women (Shah 2000), raising exposure to GH-related effects.
  • Pre-existing conditions: Pituitary adenoma (apoplexy risk), diabetes and critical illness raise risk (PMDA label, FDA bulk substances list); active cancer is a mechanistic concern from IGF-1-driven cell growth, with no GHRP-2 data.
  • Age: Cortisol release after GHRP-2 increases with age (Iranmanesh 2010), and insulin sensitivity is lower in older adults, who showed glucose rises with ibutamoren (Nass 2008).

Key Interactions & Contraindications

Documented interactions:

  • GHRH and its analogues (sermorelin, tesamorelin, CJC-1295): Combined with GHRP-2, produce synergistic GH release and larger IGF-1 increases than either alone (Van den Berghe 1997, Bowers 2004); consequence is greater IGF-1 exposure, managed by IGF-1 testing.
  • Oral estradiol therapy: Amplified GHRP-2-driven GH secretion in postmenopausal women (Shah 2000); consequence is a larger GH rise and potentially more IGF-1 exposure, gauged by IGF-1 testing.
  • Aromatase inhibitors (estrogen-blocking drugs: anastrozole, letrozole) and tamoxifen: Men taking them had smaller IGF-1 rises on a GHRP-2-containing regimen (Sigalos 2017); consequence is reduced effect.
  • Testosterone (and testosterone depletion): No interaction found; GHRP-2 efficacy was unchanged by short-term testosterone and estradiol depletion with or without testosterone add-back (Veldhuis 2009).
  • Glucocorticoids (cortisol-like steroid drugs: prednisone, dexamethasone): Blunt GH responses to GH-releasing peptides, as does infused somatostatin, per a narrative review of human studies (Ghigo 1997); consequence is reduced effect.
  • Opioid antagonists (opioid-blocking drugs: naloxone, naltrexone): No interaction found; per a review of human studies, naloxone did not affect GH release by GH-releasing peptides (Ghigo 1997).
  • Insulin and other glucose-lowering drugs (metformin, sulfonylureas): FDA cites reports of increased insulin requirement after GHRP-2 (FDA bulk substances list); consequence is loss of glucose control, mitigated by frequent glucose checks and prescriber dose review.
  • Other pituitary test agents (TRH; GnRH, gonadotropin-releasing hormone, the pituitary signal for sex hormones; CRH, corticotropin-releasing hormone, the brain signal for cortisol): Co-administration has no established safety record (PMDA label); pituitary apoplexy occurred during one such combined test (Yamamoto 2012).
  • L-arginine (supplement): Synergizes with GHRP-2 on GH release, with sex influencing the relative size (Wideman 2000); consequence is a larger GH pulse.
  • Somatostatin analogues (drugs mimicking the GH-braking hormone: octreotide, lanreotide): Octreotide blunted GHRP-2-driven GH pulse mass, frequency and regularity in healthy men (Iranmanesh 2004); consequence is a reduced effect, gauged by IGF-1 testing.
  • Nicotinic acid and its analogues (niacin, acipimox): Acipimox lowered free fatty acids and markedly amplified the GH response to GHRP-2 in older men (Van Dam 2000); consequence is greater GH and IGF-1 exposure, monitored by IGF-1 testing.
  • Recombinant GH (somatropin): Administered GH blunts the GH response to GH-releasing peptides, per a review (Ghigo 1997), while GHRP-2 partly restores secretion during GH-imposed feedback in older adults (Veldhuis 2011); consequence is excess IGF-1, fluid retention and glucose rise, gauged by IGF-1 testing.
  • Other ghrelin-receptor agonists (receptor-activating drugs: ibutamoren, ipamorelin, GHRP-6, hexarelin, anamorelin): GHRP-2 with GHRP-6 and sermorelin raised IGF-1 in men on testosterone (Sigalos 2017); consequence is additive cortisol, prolactin, appetite and glucose effects. Using one agent at a time limits this.
  • Food and exercise: Meals, glucose and fatty acids blunt the GH response, per a review (Ghigo 1997), hence fasting administration (PMDA label); strenuous exercise adds to GHRP-2’s GH response (Maas 2000).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Prolactin-raising drugs (risperidone, haloperidol, metoclopramide): Inferred from additive prolactin release; consequence is hyperprolactinemia (high prolactin) with breast discharge or low libido. Prolactin testing detects it.
  • Blood pressure-lowering drugs (amlodipine, lisinopril): Inferred from additive lowering, since the label lists low blood pressure; consequence is dizziness or fainting. Rising slowly after a dose limits this.
  • Sedating over-the-counter antihistamines (diphenhydramine, doxylamine): Inferred from additive drowsiness, a labeled reaction; consequence is impaired alertness. Spacing them apart limits overlap.

Populations who should avoid GHRP-2:

  • Pregnant women or those who may be pregnant: Absolute contraindication (PMDA label).
  • Acute critical illness (after open-heart or abdominal surgery, multiple trauma, or acute respiratory failure): FDA cites deaths of critically ill subjects after GHRP-2 (FDA bulk substances list); GH is contraindicated in these settings (DailyMed Genotropin label).
  • Active malignancy: Inferred from IGF-1-driven cell growth; no GHRP-2 data. Somatropin is contraindicated in active malignancy (DailyMed Genotropin label).
  • Active proliferative or severe non-proliferative diabetic retinopathy (diabetes-related retinal damage): Inferred from the GH rise GHRP-2 produces; somatropin is contraindicated in these grades (DailyMed Genotropin label).
  • Untreated pituitary adenoma: Apoplexy reported with a similar agent (PMDA label).
  • Insulin-treated or poorly controlled diabetes: Reports of increased insulin requirement (FDA bulk substances list).
  • Athletes tested under the World Anti-Doping Code: GHRP-2 is prohibited at all times by the World Anti-Doping Agency (WADA Prohibited List).
  • Known high prolactin or prolactinoma (a prolactin-secreting tumor): Inferred from the prolactin rise after dosing; no human data in this group.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Glucose ceiling: Monitoring covers fasting glucose and HbA1c (glycated hemoglobin, a three-month sugar average) every 3 months, halting at ≥126 mg/dL or ≥6.5%, the American Diabetes Association (ADA) cutoffs (ADA Standards 2026; its clinicians treat diabetes), preventing unrecognized diabetes.
  • IGF-1 ceiling: Protocols hold IGF-1 within the age-adjusted range, reducing or stopping above its upper limit, the Endocrine Society’s GH-therapy target (Molitch 2011; its members prescribe GH). This limits cancer, fluid and glucose risks.
  • Pause during acute illness: Use is suspended before surgery, hospitalization or serious infection and resumed after recovery, which avoids the mortality signal seen with GH-axis stimulation in critical illness.
  • Headache or vision-change rule: Sudden severe headache, vomiting or visual loss is treated as a stop-and-seek-emergency-care signal, addressing pituitary apoplexy in undiagnosed adenomas.
  • Hormone recheck: Prolactin and morning cortisol are rechecked at 3 months, with abnormal values repeated after stopping before imaging, as a narrative review proposes (Dominikowski 2026). This detects persistent prolactin or cortisol elevation.
  • Single-agent use: Combining several ghrelin-receptor agonists is avoided and each injection kept near the 1–2 µg/kg (about 100 µg) tested in humans (Arvat 1997), limiting cumulative cortisol, prolactin and glucose effects.
  • Verified product and sterile technique: Independently tested lots, sterile diluent and fresh needles, with injection sites watched, reduce contamination, immunogenicity and infection risk.
  • Slow rise after dosing: Sitting or lying briefly after injection and rising slowly reduces dizziness and falls from transient low blood pressure.

Therapeutic Protocol

Each dose below is cited; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Diagnostic regimen: One 100 µg intravenous dose in fasting adults, or 2 µg/kg in children aged 4–17 years (PMDA label).
  • Research regimens: Subcutaneous infusion of 1 µg/kg per hour for 30 days in older adults (Bowers 2004); intranasal 5–15 µg/kg two to three times daily (Pihoker 1997); oral 900 µg/kg twice daily, reflecting poor absorption (Mericq 2003).
  • Clinic regimen: A Baylor College of Medicine men’s-health practice prescribed 100 µg each of GHRP-2, GHRP-6 (a related peptide) and sermorelin subcutaneously three times daily to men on testosterone (Sigalos 2017).
  • Who popularized it: Cyril Bowers (Tulane) developed and tested most human regimens (Bowers 2012); the Baylor group of Larry Lipshultz and Alexander Pastuszak published the clinic regimen (Sigalos 2017). Online self-dosing protocols vary widely, per a narrative review (Dominikowski 2026).
  • Competing approaches: GHRP-2 alone; GHRP-2 plus a GHRH analogue for synergy (Van den Berghe 1997); oral ibutamoren, tested for a year (Nass 2008); or recombinant GH for confirmed deficiency per the Endocrine Society, whose members prescribe it (Molitch 2011).
  • Time of day: Taken fasting, as the label directs (PMDA label), since meals blunt GH responses per a review (Ghigo 1997), and often at bedtime, matching the nighttime GH surge; a late-night dose did not deepen sleep (Moreno-Reyes 1998).
  • Half-life: About 0.42–0.69 hours in adults, with peak GH 15–60 minutes after an intravenous dose (PMDA label), so each dose produces one brief GH pulse.
  • Single or split dosing: The short half-life explains split dosing two or three times daily (Pihoker 1997, Sigalos 2017); a review reports that continuous exposure desensitizes more than intermittent dosing (Ghigo 1997).
  • Genetic polymorphisms: No variant is known to guide GHRP-2 dosing; clearance is mainly biliary, with no described CYP pathway (PMDA label), so standard pharmacogenetic panels do not apply.
  • Sex differences: Peak GH does not differ by sex (Chihara 2007); women on estradiol therapy show amplified responses (Shah 2000), so IGF-1 rather than dose alone gauges exposure.
  • Age: Responses decline modestly after age 40 and after menopause (PMDA label); older adults still responded to 1 µg/kg per hour (Bowers 2004), though their glucose margin is smaller.
  • Baseline biomarkers: Baseline IGF-1 and fasting glucose set the reference for judging response and glucose drift; higher body fat blunts GH responses (Norman 2014).
  • Pre-existing conditions: Per a review, responses are reduced in hypothyroidism and obesity and nearly absent with pituitary stalk disconnection (Ghigo 1997); diabetes and pituitary tumors change the risk balance (see Interactions).

Discontinuation & Cycling

  • Short-term or lifelong: No defined course exists; human use ranges from one diagnostic dose to 18–24 months of intranasal dosing in children (Pihoker 1997), and no study supports lifelong use.
  • Withdrawal effects: None reported. Natural GH pulses and feedback persisted during GHRP-2 plus TRH infusion (Van den Berghe 1999); with ibutamoren, IGF-1 returned to baseline within a month of stopping (Nass 2008).
  • Tapering: No taper has been studied or is suggested by mechanism; stopping at once is common practice.
  • Cycling: Desensitization depends on dose and frequency (Bowers 1996), though 30-day infusion kept GH above saline levels (Bowers 2004); popular cycles, such as 8–12 weeks on and 4 off, are untested.

Sourcing and Quality

  • Regulated product: The only pharmaceutical-grade product is GHRP KAKEN 100, a 100 µg diagnostic vial from Kaken Pharmaceutical sold in Japan by prescription (PMDA label).
  • Gray-market vials: Sold online as “research chemicals”; laboratory analyses found glycine-modified GHRP-2 in seized products and undeclared GHRP-2 (about 50 µg per tablet) in a supplement (Krug 2018, Thomas 2010).
  • US compounding status: FDA lists injectable and nasal GHRP-2 among bulk substances that may present significant safety risks for outsourcing-facility compounding (large-scale pharmacy production), citing aggregation, impurities and an unnatural amino acid (FDA bulk substances list).
  • What to look for: Lot-specific identity and purity results from an independent laboratory using mass spectrometry (a molecular identity test), plus endotoxin and sterility testing; such reports reduce but do not remove contamination risk.
  • Formulation and storage: The approved vial is stored at or below 10 °C without freezing, and the dissolved solution is used promptly, with stability confirmed for 24 hours at room temperature (PMDA label).
  • Reputable brands: Outside Japan, no GHRP-2 brand or compounding pharmacy has publicly verified pharmaceutical-grade quality.

Practical Considerations

  • Time to effect: GH peaks within 15–60 minutes (PMDA label) and IGF-1 rises within a day (Van den Berghe 1997); by analogy with ibutamoren, any body-composition change would take months (Nass 2008).
  • Common pitfalls: Dosing after meals, equating a GH rise with health benefit, stacking several ghrelin-receptor agonists, trusting untested vials, and skipping glucose and IGF-1 checks.
  • Regulatory status: In the US, FDA lists GHRP-2 among compounding substances that may present significant safety risks (FDA bulk substances list); approved in Japan only as a diagnostic (PMDA label); prohibited at all times in sport (WADA Prohibited List).
  • Cost and access: Gray-market vials cost far less than recombinant GH but legal, quality-assured access outside Japan is essentially absent. With no patent-protected market, neither manufacturers nor payers have an incentive to fund outcome trials, a structural reason the evidence gap persists.

Interaction with Foundational Habits

  • Sleep: No direct benefit shown. A single late-night intravenous dose did not increase slow-wave (deep) sleep and tended to increase wakefulness in the following hour (Moreno-Reyes 1998); drowsiness is a labeled reaction (PMDA label). Bedtime dosing matches natural GH timing but has no proven sleep advantage.
  • Nutrition: Interaction is blunting and potentiating. Meals, glucose and fatty acids blunt the GH response, per a review (Ghigo 1997), so doses are taken fasting; GHRP-2 raises hunger and intake (Laferrère 2005), which favors planned, protein-rich meals over extra snacking.
  • Exercise: Interaction is additive. Strenuous exercise plus GHRP-2 produced larger GH responses than exercise alone (Maas 2000), and exercise potentiated GHRP-2’s GH action (Wideman 2000); no study shows added strength or muscle gains.
  • Stress management: Interaction is direct. Each dose acutely raises ACTH and cortisol, comparable to a corticotropin-releasing hormone test (Arvat 1997), with larger cortisol responses at older ages (Iranmanesh 2010); no study addresses chronic stress, but dosing away from stressful periods limits cortisol stacking.

Monitoring Protocol & Defining Success

Before starting, a baseline panel records the hormones GHRP-2 changes and screens for conditions that raise its risks: IGF-1, fasting glucose, HbA1c, prolactin, morning cortisol, ALT, a white blood cell count and, for women who could become pregnant, a pregnancy test.

Ongoing monitoring follows this cadence: IGF-1 and fasting glucose at 4–6 weeks, then every 3 months while in use; prolactin, morning cortisol, ALT and white blood cell count at 3 months, then every 6 months; HbA1c every 3 months. Abnormal hormone results are repeated after stopping before further workup, as a narrative review proposes (Dominikowski 2026). Success means a sustained IGF-1 rise within the age-adjusted range, stable glucose and the hoped-for functional change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 Within the age-adjusted reference range, not above its upper limit (Endocrine Society target for GH therapy) Expected change; shows effect and excess Source: Molitch 2011; the Endocrine Society’s members prescribe GH therapy. Conventional reference range: the laboratory’s age- and sex-specific interval. Same laboratory each time; no fasting needed.
Fasting glucose 70–99 mg/dL (standard reference range) Safety check; rise changes use 8-hour fast; draw before the morning dose; pair with HbA1c and fasting insulin.
HbA1c 4.0–5.6% (standard reference range) Safety check; rise changes use No fasting needed; reflects about 3 months, so first useful recheck is at 3 months.
Prolactin Men about 2–18 ng/mL; non-pregnant women about 2–29 ng/mL (standard reference range) Safety check; persistent rise changes use Draw rested, not within hours of a dose, which raises prolactin transiently.
Morning cortisol About 5–25 µg/dL at 8 a.m. (standard reference range) Safety check; persistent rise changes use Draw 7–9 a.m., before the day’s dose; GHRP-2 raises cortisol acutely.
ALT About 7–56 U/L (standard reference range) Safety check; labeled liver-enzyme rise Avoid strenuous exercise 48 hours before testing; ranges vary by laboratory.
White blood cell count About 4.5–11.0 × 10⁹/L (standard reference range) Safety check; labeled rise Part of a complete blood count; recent infection also raises it.
Pregnancy test Negative (standard reference range for non-pregnant women) Safety check; pregnancy is a contraindication Measures hCG (human chorionic gonadotropin) in urine or blood; for women who could become pregnant, before starting.

Qualitative markers:

  • Hunger and appetite between meals
  • Sleep quality and daytime drowsiness
  • Swelling of hands or feet, tingling in the fingers
  • Joint or muscle aches
  • Warmth or flushing after doses
  • Injection-site redness or pain
  • Energy, exercise recovery and waist circumference

Emerging Research

  • No registered GHRP-2 treatment trials: ClinicalTrials.gov lists GHRP-2 only as a test agent in hormone-physiology studies such as NCT00309855 (completed 2008; no registry results; published as Iranmanesh 2010: GHRP-2 raised cortisol, more with age). Outcome evidence for longevity use is therefore not imminent.
  • Oral ghrelin-receptor agonist in children (NCT06948214): Phase 3, 150 GH-deficient children, daily LUM-201 (ibutamoren) versus placebo for 12 months; primary endpoint annual height velocity; recruiting, primary completion December 2027. A positive result would show the class can deliver clinical growth, unlike GHRP-2’s null pediatric trial; a null result would extend that failure.
  • Long-term class safety (NCT05796440): Phase 2 extension in 60 children continuing LUM-201, primary endpoint treatment-emergent adverse events, completion April 2028. A clean safety record would modestly reassure about sustained ghrelin-receptor stimulation; excess adverse events would strengthen the risk case for GHRP-2.
  • Ghrelin-receptor blockade for aging muscle: Deleting or blocking the receptor improved endurance and strength in aged mice without changing lifespan (Kerr 2026). Human translation would weaken the rationale for receptor stimulation in older adults.
  • Long-term outcomes gap: The closest evidence is a two-year ibutamoren trial with lean-mass gains but no strength or function change (Nass 2008); a GHRP-2 trial with function, fracture or cardiometabolic endpoints would be needed to move any benefit beyond Low.
  • Regulatory review: FDA’s list, updated April 22, 2026, places several peptides (such as BPC-157 and CJC-1295) in a “nominated but withdrawn” group while GHRP-2 remains in the safety-risk category (FDA bulk substances list); reclassification would change legal access, not the evidence.

Conclusion

GHRP-2 is a small laboratory-made protein fragment that copies the hunger hormone ghrelin and makes the pituitary gland release short bursts of growth hormone. Its one approved use, in Japan, is a single-dose test for growth hormone deficiency, and for that purpose the evidence is solid. For health-focused adults weighing it as a longevity tool, the picture is much thinner. Human studies show that it raises growth hormone and the growth factor that follows it, and that it increases hunger, but none has shown better muscle function, body composition, sleep, heart health or lifespan in adults. A related oral compound added lean body mass without added strength, and a large trial in children found no growth benefit. Animal studies suggest heart and tissue protection, yet damping the same receptor helps aging muscle in mice, and people with naturally low growth hormone signaling are unusually protected from cancer and diabetes.

The known downsides are mostly short-lived: warmth, flushing, hunger, drowsiness and brief rises in the stress hormone cortisol and the milk-production hormone prolactin. Longer-term concerns, such as higher blood sugar, fluid retention and a possible cancer signal, rest on indirect evidence. The US drug regulator lists it as a safety risk for pharmacy-made versions, and unregulated products have contained the wrong substances. Much of the human research comes from the peptide’s developer and its Japanese manufacturer. Overall, the case for GHRP-2 in health and longevity rests on hormone changes rather than on shown health outcomes.

Top - Benefits - Risks - Protocol